Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor

被引：0
|
作者：
Simon J. B. Aylwin
Istvan Bodi
Ronald Beaney
机构：
[1] King’s College Hospital,Department of Endocrinology
[2] King’s College Hospital,Department of Clinical Neuropathology
[3] Guy’s & St Thomas’ Hospital Cancer Centre,Department of Neuro
来源：
Pituitary | 2016年 / 19卷
关键词：
Vemurafenib; Craniopharyngioma; Prolactinoma; BRAF Inhibitor; BRAF V600E Mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：544 / 546
页数：2
相关论文
共 50 条
  • [1] Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
    Aylwin, Simon J. B.
    Bodi, Istvan
    Beaney, Ronald
    PITUITARY, 2016, 19 (05) : 544 - 546
  • [2] Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
    Chik, Constance L.
    van Landeghem, Frank K. H.
    Easaw, Jacob C.
    Mehta, Vivek
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (05)
  • [3] A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
    Maleka, A.
    Astrom, G.
    Bystrom, P.
    Ullenhag, G. J.
    BMC CANCER, 2016, 16
  • [4] A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
    A. Maleka
    G. Åström
    P. Byström
    G. J. Ullenhag
    BMC Cancer, 16
  • [5] BRAF plus MEK inhibition effective in papillary craniopharyngioma
    Peter Sidaway
    Nature Reviews Clinical Oncology, 2023, 20 : 661 - 661
  • [6] BRAF plus MEK inhibition effective in papillary craniopharyngioma
    Sidaway, Peter
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (10) : 661 - 661
  • [7] Papillary craniopharyngioma management in the era of BRAF and MEK inhibition
    Damante, Mark
    Cua, Santino
    Kreatsoulas, Daniel
    Giglio, Pierre
    Ghalib, Luma
    Biswas, Chandrima
    Wu, Kyle C.
    Prevedello, Daniel M.
    JOURNAL OF NEURO-ONCOLOGY, 2025,
  • [8] Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma
    Khaddour, Karam
    Chicoine, Michael R.
    Huang, Jiayi
    Dahiya, Sonika
    Ansstas, George
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (12): : 1590 - 1595
  • [9] Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
    Ali, Siraj M.
    He, Je
    Carson, Wade
    Stephens, Phil J.
    Fiorillo, Joseph
    Lipson, Doron
    Palmer, Gary A.
    Ross, Jeffrey S.
    Miller, Vincent A.
    Sharman, Jeffrey
    CASE REPORTS IN ONCOLOGY, 2014, 7 (02): : 343 - 348
  • [10] Refractory Multisystem Langerhans Cell Histiocytosis: Response to Braf Inhibitor Vemurafenib - A Case Report
    Willis, C.
    Barclay, C.
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S496 - S496
12345